Investor Relations

Investor Relations

SciGen Ltd is a high growth biopharmaceutical company manufacturing and delivering high quality, low cost healthcare products globally. The Company is generating revenues through its portfolio of generic, biosimilar and proprietary drugs. The Company has been listed on the Australian Stock Exchange (ASX: SIE) since 2002.

Company & Stock Data

Investment Information

Key Investment Information

Market Capitalisation:
A$27.62m (based on the share price on 13 Apr 2017)

Official Listing Date:
Nov 2002

Capital Structure

Ordinary shares on issue:
552.3m

Options (fully diluted):
0m

Convertible notes/other:
0

Substantial shareholders

Bioton S.A.:
95.57%

Cash at 31 March 2017:
USD$4.54m

Presentations

Annual Reports

> View previous annual reports